SCHEMBL2904151

SCHEMBL2904151

COC(=O)c1cccc(-c2cc(C)c(OCCOC(C)=O)nc2C)c1C

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 5/20 0.39
▸ KDM4E B2RXH2 2/20 0.39
▸ PDCD1 Q15116 2/20 0.37
▸ CD274 Q9NZQ7 2/20 0.37
▸ VDR P11473 2/20 0.36
▸ HSD17B10 Q99714 1/20 0.36
▸ MAPT P10636 2/20 0.35
▸ HSP90AA1 P07900 1/20 0.35
▸ HTT P42858 1/20 0.35
▸ NPSR1 Q6W5P4 1/20 0.35
▸ SLC6A2 P23975 1/20 0.35
▸ SLC6A4 P31645 1/20 0.35
▸ SLC6A3 Q01959 1/20 0.35
▸ MEN1 O00255 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ DRD1 P21728 1/20 0.34
▸ LMNA P02545 1/20 0.34
▸ GAA P10253 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13117464 0.84 ALDH1A1 (0.39) ALDH1A1KDM4EPDCD1CD274VDR
SCHEMBL13117462 0.84 ALDH1A1 (0.39) ALDH1A1KDM4EPDCD1CD274VDR
SCHEMBL13117466 0.84 ALDH1A1 (0.39) ALDH1A1KDM4EPDCD1CD274VDR
SCHEMBL13117630 0.83 CD274 (0.38) KDM4EPDCD1CD274HSD17B10HTT
SCHEMBL13117459 0.83 KDM4E (0.42) ALDH1A1KDM4EPDCD1CD274VDR
SCHEMBL13117609 0.83 PDCD1 (0.35) ALDH1A1PDCD1CD274MAPTHTT
SCHEMBL13213445 0.82 ALDH1A1 (0.37) ALDH1A1KDM4EPDCD1CD274VDR
SCHEMBL13213444 0.81 ALDH1A1 (0.37) ALDH1A1KDM4EPDCD1CD274VDR
SCHEMBL13117473 0.81 MAPT (0.42) ALDH1A1KDM4EPDCD1CD274HSD17B10
SCHEMBL13117454 0.81 KDM4E (0.38) ALDH1A1KDM4EPDCD1CD274VDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100267775-A1 OXADIAZOLIDINEDIONE COMPOUND ASTELLAS PHARMA INC. (JP) 2010-10-21 — — US disclosed
US-20100267775-A1 OXADIAZOLIDINEDIONE COMPOUND ASTELLAS PHARMA INC. (JP) 2010-10-21 — — US disclosed
EP-2216330-A1 OXADIAZOLIDINEDIONE COMPOUND Astellas Pharma Inc. (JP) 2010-08-11 — — EP disclosed
EP-2216330-A1 OXADIAZOLIDINEDIONE COMPOUND Astellas Pharma Inc. (JP) 2010-08-11 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100267775-A1 OXADIAZOLIDINEDIONE COMPOUND GPR119, GLP1R, GPR4 ALDH1A1 2370/4885KDM4E 2459/4885PDCD1 1246/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback